{"id":2613,"date":"2022-01-10T13:03:39","date_gmt":"2022-01-10T13:03:39","guid":{"rendered":"https:\/\/grail.com\/?post_type=press-release&p=2613"},"modified":"2022-01-10T13:43:23","modified_gmt":"2022-01-10T13:43:23","slug":"grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test","status":"publish","type":"press-release","link":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/","title":{"rendered":"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test"},"content":{"rendered":"

GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test<\/strong><\/p>\n

\u2013<\/i>Collaboration expected to accelerate identification of patients with an elevated risk for cancer\u2013<\/i><\/em><\/p>\n

MENLO PARK, Calif. and CHARLOTTE, N.C., January 10, 2022 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Premier, Inc.\u2019s PINC AI\u2122, an advanced technology and services platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri\u00ae<\/sup>, GRAIL\u2019s groundbreaking multi-cancer early detection blood test.<\/p>\n

Under the partnership, Premier\u2019s PINC AI will augment its AI-enabled clinical decision support technology to alert clinicians to patients who present an elevated risk of cancer and may benefit from early detection with the Galleri test. The alert will be evidence-based, integrated in the workflow and is expected to be compatible with existing electronic medical record systems. Indianapolis-based Community Health Network is expected to be the first health system to pilot candidate alerts.<\/p>\n

\u201cAt GRAIL, we are steadfast in our mission to detect cancer early. We are committed to making Galleri available to healthcare providers and eligible patients as a complement to guideline recommended cancer screenings, because we know that most cancers are diagnosed too late, when outcomes are poor,\u201d said Dr. Joshua Ofman, president and chief medical officer at GRAIL. \u201cThe partnership with Premier\u2019s PINC AI, a trusted leader in healthcare technology, will support a key pillar of new early cancer detection technology \u2013 the identification of eligible patients through healthcare providers\u2019 existing workflows.\u201d<\/p>\n

\u201cPINC AI augments clinical intelligence and helps ensure patients receive evidence-based care,\u201d said Leigh Anderson, president of Premier\u2019s PINC AI. \u201cOur goal with the new candidate alerts is to ensure more patients who need a cancer screening get one. We believe that Galleri is a game-changing screening tool that has the potential to increase early detection and treatment that can save lives, improve quality and reduce unnecessary costs.\u201d<\/p>\n

More than 600,000 people die from cancer each year in the U.S., according to the American Cancer Society. This is in large part because the majority of cancers are found in later stages when treatment options are limited. Recommended screening tests only cover five cancer types in the U.S.: breast, colon, cervical, prostate, and, in high-risk smokers, lung. More than 70 percent of cancer deaths are from cancers that lack recommended early detection screening.<\/p>\n

In addition, studies<\/a> have demonstrated that stage at diagnosis has the greatest impact on costs, with decreased costs for patients diagnosed early in the disease compared to those diagnosed at later stages.<\/p>\n

\u201cGalleri is a validated and transformational test that can detect more than 50 cancers with a single blood draw and predict the origin with a high degree of accuracy and a low rate of false positives,\u201d said Patrick McGill, M.D., executive vice president and chief transformation officer at Community Health Network. \u201cWith this collaboration between PINC AI and GRAIL, our clinicians will be alerted when patients meet certain criteria for the ordering of a Galleri test. We believe this will make Community Health Network much more effective in our efforts to detect cancers early, when treatments are more effective, giving our patients the best chances of a successful outcome. Thanks to Community Health Network\u2019s Foundation sponsorship and funding, we are proud to be the first health system taking advantage of this collaboration.\u201d<\/p>\n

Galleri is available in the U.S. by prescription only to complement existing single cancer screening tests.<\/p>\n

About Galleri<\/strong><\/p>\n

The earlier that cancer is detected, the higher the chance of successful outcomes. The Galleri multi-cancer early detection test can detect more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the cancer signal origin, or where the cancer is located in the body, with high accuracy to help guide the next steps to diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is intended for use in people with an elevated risk of cancer, such as those aged 50 or older.<\/p>\n

For more information about Galleri, visit www.galleri.com<\/a>.<\/p>\n

About GRAIL<\/strong><\/p>\n

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a wholly-owned subsidiary of Illumina, Inc. (NASDAQ:ILMN). For more information, please visit www.grail.com<\/a>.<\/p>\n

About PINC AI<\/strong><\/p>\n

PINC AI<\/a>\u2122<\/u> is the technology and services platform of Premier Inc<\/a>. (NASDAQ: PINC). Made up of 20 years\u2019 worth of cost, quality and operational data gleaned from over 45 percent of U.S. hospital discharges annually, as well as 812 million hospital outpatient and clinic encounters and 131 million physician office visits, PINC AI provides actionable intelligence that helps improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI offerings rely on advanced analytics to identify improvement opportunities, consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change. PINC AI is also the data engine powering Premier\u2019s newest brands \u2013 Remitra\u2122\u00a0 and Contigo Health\u00ae. With a leading network of provider organizations, PINC AI accelerates ingenuity and serves as a large-scale innovation catalyst in healthcare. Premier, Inc, is headquartered in Charlotte, N.C.. PINC AI can be followed on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

Important Galleri Safety Information<\/strong><\/p>\n

Galleri is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located.<\/p>\n

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of \u201cCancer Signal Not Detected\u201d does not rule out cancer. A test result of \u201cCancer Signal Detected\u201d requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.<\/p>\n

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Galleri is prescription only.<\/p>\n

Laboratory\/Test Information <\/strong><\/p>\n

GRAIL\u2019s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has been approved by New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP). The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL\u2019s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.<\/p>\n","protected":false},"excerpt":{"rendered":"

GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test \u2013Collaboration expected to accelerate identification of patients with an elevated risk for cancer\u2013 MENLO PARK, Calif. and CHARLOTTE, N.C., January 10, 2022 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can […]<\/p>\n","protected":false},"featured_media":1787,"parent":0,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2613","press-release","type-press-release","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nGRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test - GRAIL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test - GRAIL\" \/>\n<meta property=\"og:description\" content=\"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test \u2013Collaboration expected to accelerate identification of patients with an elevated risk for cancer\u2013 MENLO PARK, Calif. and CHARLOTTE, N.C., January 10, 2022 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/\" \/>\n<meta property=\"og:site_name\" content=\"GRAIL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/grailbio\/\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-10T13:43:23+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/grail.com\/wp-content\/uploads\/2020\/12\/summit-hero.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"720\" \/>\n\t<meta property=\"og:image:height\" content=\"894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@grailbio\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/\",\"url\":\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/\",\"name\":\"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test - GRAIL\",\"isPartOf\":{\"@id\":\"https:\/\/grail.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/summit-hero.jpg\",\"datePublished\":\"2022-01-10T13:03:39+00:00\",\"dateModified\":\"2022-01-10T13:43:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#primaryimage\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/summit-hero.jpg\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/summit-hero.jpg\",\"width\":720,\"height\":894},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/grail.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/grail.com\/#website\",\"url\":\"https:\/\/grail.com\/\",\"name\":\"GRAIL\",\"description\":\"Detect cancer early, when it can be cured\",\"publisher\":{\"@id\":\"https:\/\/grail.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/grail.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/grail.com\/#organization\",\"name\":\"GRAIL, LLC\",\"url\":\"https:\/\/grail.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"width\":512,\"height\":512,\"caption\":\"GRAIL, LLC\"},\"image\":{\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/grailbio\/\",\"https:\/\/x.com\/grailbio\",\"https:\/\/www.linkedin.com\/company\/grail-inc.\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test - GRAIL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/","og_locale":"en_US","og_type":"article","og_title":"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test - GRAIL","og_description":"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test \u2013Collaboration expected to accelerate identification of patients with an elevated risk for cancer\u2013 MENLO PARK, Calif. and CHARLOTTE, N.C., January 10, 2022 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can […]","og_url":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/","og_site_name":"GRAIL","article_publisher":"https:\/\/www.facebook.com\/grailbio\/","article_modified_time":"2022-01-10T13:43:23+00:00","og_image":[{"width":720,"height":894,"url":"http:\/\/grail.com\/wp-content\/uploads\/2020\/12\/summit-hero.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@grailbio","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/","url":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/","name":"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test - GRAIL","isPartOf":{"@id":"https:\/\/grail.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#primaryimage"},"image":{"@id":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#primaryimage"},"thumbnailUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/summit-hero.jpg","datePublished":"2022-01-10T13:03:39+00:00","dateModified":"2022-01-10T13:43:23+00:00","breadcrumb":{"@id":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#primaryimage","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/summit-hero.jpg","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/summit-hero.jpg","width":720,"height":894},{"@type":"BreadcrumbList","@id":"https:\/\/grail.com\/press-releases\/grail-and-premiers-pinc-ai-partner-to-support-patient-access-to-galleri-multi-cancer-early-detection-blood-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/grail.com\/"},{"@type":"ListItem","position":2,"name":"GRAIL and Premier\u2019s PINC AI\u2122 Partner to Support Patient Access to Galleri\u00ae Multi-Cancer Early Detection Blood Test"}]},{"@type":"WebSite","@id":"https:\/\/grail.com\/#website","url":"https:\/\/grail.com\/","name":"GRAIL","description":"Detect cancer early, when it can be cured","publisher":{"@id":"https:\/\/grail.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/grail.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/grail.com\/#organization","name":"GRAIL, LLC","url":"https:\/\/grail.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","width":512,"height":512,"caption":"GRAIL, LLC"},"image":{"@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/grailbio\/","https:\/\/x.com\/grailbio","https:\/\/www.linkedin.com\/company\/grail-inc.\/"]}]}},"_links":{"self":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/2613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/types\/press-release"}],"version-history":[{"count":0,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/2613\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media\/1787"}],"wp:attachment":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media?parent=2613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}